Zhijie Wang
Clinical trials sponsored by Zhijie Wang, explained in plain language.
-
New drug combo targets rare, aggressive lung cancer in early trial
Disease control Not yet recruitingThis study tests a new two-in-one immunotherapy drug (iparomlimab and tuvonralimab) combined with standard chemotherapy as a first treatment for people with a specific, hard-to-treat type of advanced lung cancer (SMARCA4-deficient NSCLC). The goal is to see if this combination ca…
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 03, 2026 21:04 UTC
-
Promising combo targets rare lung cancer in new trial
Disease control Not yet recruitingThis study tests a combination of anlotinib pills and standard chemotherapy for people with a rare, advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combo can delay cancer growth and what side effects occur. About 28 adults will receive the treatment i…
Phase: PHASE2 • Sponsor: Zhijie Wang • Aim: Disease control
Last updated May 01, 2026 15:57 UTC